Boulding Mark Elliott

Exec. VP And CLO | Exec. VP And CLO

1 company

Good

Trades Analyzed

12M Win Rate

30.0%

Avg 3M Return

+0.4%

Avg 12M Return

-12.5%

Boulding Mark Elliott is an Exec. VP And CLO at PTC THERAPEUTICS, INC.. Recent SEC Form 4 filings include 0 buys and 27 sells.

Estimated insider holdings value: $8.5M based on current market prices.

Holdings by Company

PTCTApr 6, 2026

Current Shares107.5K

Value$8.49M

Net Activity-635,367

Bought: 0Sold: 635.4K

Showing 10 filings (page 2)

Date	Ticker	Role	Type	Shares	Price	Value	Chg%	3M	12M
Mar 12, 2025	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	15,521	$53.30	$827,232.91	-7.0%	-3.5%	+18.2%
Mar 11, 2025	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	75,420	$53.08	$4,003,304.97	-10.7%	-1.7%	+24.9%
Feb 20, 2025	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sell	2,947	$50.11	$147,678.10	-1.4%	-8.3%	+40.3%
Jan 8, 2025	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sell	3,541	$44.87	$158,870.62	-1.6%	-11.7%	+70.6%
Dec 3, 2024	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	95,908	$52.37	$5,022,334.27	-12.9%	+5.1%	+50.6%
Jan 30, 2024	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sell	794	$27.25	$21,637.14	-1.1%	+21.0%	+70.3%
Jan 9, 2024	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sell	3,395	$28.85	$97,959.60	-2.3%	-6.4%	+56.9%
Apr 17, 2023	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	61,923	$51.42	$3,183,830.19	-29.1%	-25.1%	-51.0%
Jan 31, 2023	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sell	812	$45.63	$37,049.94	-1.1%	+20.2%	-43.1%
Jan 11, 2023	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sell	1,085	$43.58	$47,288.41	-0.7%	+6.1%	-37.1%